Takeda logo

Takeda Oncology's Commitment to Advancing Metastatic Colorectal Cancer | Takeda Oncology

Dedicated to Finding Innovative Solutions in Metastatic Colorectal Cancer


Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related mortalities worldwide. With the global incidence of mCRC on the rise, treatment advancements in efficacy and tolerability are vital. Takeda Oncology is committed to bringing innovative solutions to evolve the treatment landscape in mCRC.


All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23